The log-rank test revealed no significant differences in rates of rPFS, bPFS, PFS, and OS, or toxicity across stratification factors (including clinical T stage, Gleason score, pre-radiotherapy PSA level, number of metastatic lesions, presence of bone or distant metastasis, ARPI use, and 1-month post-radiotherapy PSA level; Supplementary Table A2). The gene discussed is KLK3; the disease is metastasis.